Medtronic plc, a global leader in healthcare technology, today announced the launch of the Stedi™  Extra Support guidewire, designed to enhance performance of the Evolut™ transcatheter aortic valve replacement (TAVR) platform – and compatible with all commercially available TAVR systems – for patients with severe aortic stenosis.

美敦力公司（Medtronic plc），作为全球医疗技术的领导者，今天宣布推出Stedi™ Extra Support导丝，旨在提升Evolut™经导管主动脉瓣置换术（TAVR）平台的性能，并且该导丝兼容所有商用TAVR系统，适用于重度主动脉瓣狭窄患者。

The announcement was made during the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, Calif..

该公告是在2025年加利福尼亚州旧金山举行的经导管心血管治疗（TCT）会议上发布的。

Severe aortic stenosis occurs when the aortic valve leaflets become stiff and thickened and have difficulty opening and closing, making the heart work harder to pump blood to the rest of the body. Severe aortic stenosis often reduces a patient's quality of life and limits their daily activities. If left untreated, patients with symptomatic severe aortic stenosis can die from heart failure in as little as two years..

当主动脉瓣叶变得僵硬和增厚，并且难以打开和关闭时，就会发生严重的主动脉瓣狭窄，这使得心脏必须更加努力地将血液泵送到身体的其他部位。严重的主动脉瓣狭窄常常降低患者的生活质量，并限制他们的日常活动。如果不进行治疗，有症状的严重主动脉瓣狭窄患者可能在短短两年内心力衰竭而死亡。

The Evolut™ TAVR system provides a minimally invasive solution for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate, and low).

Evolut™ TAVR系统为所有风险类别（极高危、高危、中危和低危）的症状性重度主动脉瓣狭窄患者提供了一种微创解决方案。

Engineered to complement the Evolut platform, the Stedi guidewire delivers enhanced support for stability, safety and predictability during valve deployment

为配合Evolut平台而设计，Stedi导丝在瓣膜展开过程中提供更高的稳定性、安全性和可预测性支持。

without requiring changes to implant technique. Developed specifically for TAVR procedures, Stedi combines a stiff proximal main body, gradual stiffness transition, and distal curve designed for stability, predictability, and safety.

无需改变植入技术。Stedi专为TAVR手术设计，结合了坚硬的近端主体、渐变的刚度过渡以及旨在提高稳定性、可预测性和安全性的远端弯曲。

“The Stedi Extra Support guidewire represents a meaningful advancement in TAVR,” said Tanvir J. Bajwa, MD, interventional cardiologist at Advocate Health.  “It enhances stability and predictability during valve deployment, especially when paired with techniques like simplified cusp  overlap, and reinforces procedural consistency with the Evolut platform.

“Stedi Extra Support导丝代表了TAVR领域的一项重要进步，”Advocate Health的心脏介入医生Tanvir J. Bajwa博士说道。“它在瓣膜释放过程中增强了稳定性和可预测性，特别是与简化瓣叶重叠等技术结合使用时，并通过Evolut平台进一步强化了手术的一致性。”

This innovation supports more  predictable outcomes and the precision we strive for in treating patients with severe aortic stenosis.”.

这一创新支持更可预测的结果，以及我们在治疗严重主动脉瓣狭窄患者时所追求的精确性。

Bench testing in a simulated anatomy has demonstrated that use of the Stedi guidewire, during deployment, when compared to less supportive wires with the Evolut platform, provides a reduction in ventricular movement, improved stability, and a more coaxial deployment.

在模拟解剖学中的台架测试表明，与使用Evolut平台时支撑力较弱的导丝相比，在展开过程中使用Stedi导丝可减少心室运动、提高稳定性并实现更同轴的展开。

Additionally, when used with the cusp overlap technique, extra support guidewires have been shown to be associated with a lower rate of permanent pacemaker implantation at 30 days.

此外，当与尖端重叠技术一起使用时，额外的支撑导丝已被证明与 30 天内较低的永久性起搏器植入率相关。

“We continue to build a meaningful portfolio of procedural solutions which improve long-term outcomes for patients with aortic stenosis and advance the future of TAVR,” said Jorie Soskin, vice president and general manager of the Structural Heart business within the Cardiovascular Portfolio at Medtronic.

“我们继续构建有意义的手术解决方案组合，以改善主动脉瓣狭窄患者的长期预后，并推动TAVR的未来发展，”美敦力心血管产品组合中结构性心脏业务的副总裁兼总经理Jorie Soskin表示。

“The Stedi guidewire is a complementary addition to our growing TAVR portfolio—purposefully designed to meet the evolving needs of physicians today and for the future, delivering enhanced stability and predictability while seamlessly integrating into existing Evolut workflows. Its thoughtful design supports procedural precision that can help drive improved patient-specific outcomes.”.

“Stedi导丝是我们不断扩展的TAVR产品组合的一个有力补充——它旨在满足当今和未来医生不断变化的需求，提供更高的稳定性和可预测性，同时无缝融入现有的Evolut工作流程。其周到的设计支持手术精确性，有助于推动改善针对患者的特定结果。”

The Stedi™ Extra Stiff Guidewire has U.S. Food and Drug Administration clearance and is currently available in the United States.

Stedi™超硬导丝已获得美国食品药品监督管理局的批准，目前在美国有售。

For more information, visit

欲了解更多信息，请访问

https://medtronic.com/content/dam/medtronic-wide/public/united-states/products/cardiac-vascular/cardiovascular/guidewires/stedi-extra-support-guidewire-brochure.pdf

https://medtronic.com/content/dam/medtronic-wide/public/united-states/products/cardiac-vascular/cardiovascular/guidewires/stedi-extra-support-guidewire-brochure.pdf

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更果敢的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找和发现解决方案，大胆攻克人类面临的最严峻健康问题。我们的使命——减轻病痛、恢复健康、延长生命——团结了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们广泛的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

随着我们推动以洞察力为导向的护理、以人为本的体验以及为我们的世界带来更好的结果，期待我们做得更多。在我们所做的一切中，我们正在创造非凡。欲了解有关美敦力的更多信息，请访问。